Khachatryan Tigran, Shafie Mohammad, Abcede Hermelinda, Shah Jay, Nagamine Masaki, Granstein Justin, Yuki Ichiro, Golshani Kiarash, Suzuki Shuichi, Yu Wengui
Department of Neurology, University of California, Irvine, Irvine, CA, United States.
Department of Neurological Surgery, University of California, Irvine, Irvine, CA, United States.
Front Neurol. 2023 Jun 16;14:1181295. doi: 10.3389/fneur.2023.1181295. eCollection 2023.
In this review article, we summarized the current advances in rescue management for reperfusion therapy of acute ischemic stroke from large vessel occlusion due to underlying intracranial atherosclerotic stenosis (ICAS). It is estimated that 24-47% of patients with acute vertebrobasilar artery occlusion have underlying ICAS and superimposed thrombosis. These patients have been found to have longer procedure times, lower recanalization rates, higher rates of reocclusion and lower rates of favorable outcomes than patients with embolic occlusion. Here, we discuss the most recent literature regarding the use of glycoprotein IIb/IIIa inhibitors, angioplasty alone, or angioplasty with stenting for rescue therapy in the setting of failed recanalization or instant/imminent reocclusion during thrombectomy. We also present a case of rescue therapy post intravenous tPA and thrombectomy with intra-arterial tirofiban and balloon angioplasty followed by oral dual antiplatelet therapy in a patient with dominant vertebral artery occlusion due to ICAS. Based on the available literature data, we conclude that glycoprotein IIb/IIIa is a reasonably safe and effective rescue therapy for patients who have had a failed thrombectomy or have residual severe intracranial stenosis. Balloon angioplasty and/or stenting may be helpful as a rescue treatment for patients who have had a failed thrombectomy or are at risk of reocclusion. The effectiveness of immediate stenting for residual stenosis after successful thrombectomy is still uncertain. Rescue therapy does not appear to increase the risk of sICH. Randomized controlled trials are warranted to prove the efficacy of rescue therapy.
在这篇综述文章中,我们总结了因颅内动脉粥样硬化狭窄(ICAS)导致大血管闭塞的急性缺血性卒中再灌注治疗的挽救管理方面的当前进展。据估计,24%至47%的急性椎基底动脉闭塞患者存在潜在的ICAS并伴有叠加血栓形成。已发现这些患者与栓塞性闭塞患者相比,手术时间更长、再通率更低、再闭塞率更高且良好预后率更低。在此,我们讨论了关于在血栓切除术期间再通失败或即刻/即将发生再闭塞的情况下,使用糖蛋白IIb/IIIa抑制剂、单纯血管成形术或血管成形术联合支架置入术进行挽救治疗的最新文献。我们还介绍了一例因ICAS导致优势椎动脉闭塞的患者,在静脉注射组织型纤溶酶原激活剂(tPA)和血栓切除术后,采用动脉内替罗非班和球囊血管成形术进行挽救治疗,随后进行口服双联抗血小板治疗的病例。基于现有文献数据,我们得出结论,对于血栓切除术失败或残留严重颅内狭窄的患者,糖蛋白IIb/IIIa是一种合理安全且有效的挽救治疗方法。球囊血管成形术和/或支架置入术对于血栓切除术失败或有再闭塞风险的患者可能作为挽救治疗有帮助。成功血栓切除术后立即对残留狭窄进行支架置入的有效性仍不确定。挽救治疗似乎不会增加症状性颅内出血(sICH)的风险。需要进行随机对照试验以证明挽救治疗的疗效。